Actively Recruiting
Implementation of Transcranial Magnetic Stimulation for Smoking Cessation
Led by Centre for Addiction and Mental Health · Updated on 2026-03-27
40
Participants Needed
1
Research Sites
221 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Repetitive transcranial magnetic stimulation (rTMS) is an alternative non-invasive treatment to help people quit smoking. rTMS uses a magnetic field to stimulate regions of the brain that are involved in addiction. The two brain regions that are stimulated are the insula and the dorsolateral prefrontal cortex, which are involved in drug craving and decision-making, respectively. The goal of this clinical trial is to learn more about the feasibility of offering rTMS as a treatment in the Nicotine Dependence Clinic (NDC) to help daily smokers to quit smoking. The NDC is at the Center for Addiction and Mental Health (CAMH) at 1025 Queen Street West, in Toronto, Canada. Participants will be asked to come to CAMH to: * Complete surveys and optional interviews to learn more about their opinions and experiences with this treatment * Start a treatment course that includes 3 weeks of daily (Monday to Friday) rTMS sessions followed by 3 weeks of weekly rTMS sessions for a total of 6 weeks. Each session lasts about 25 minutes and is provided by an rTMS technician with medical supervision. Objectives • Learning about the feasibility of rTMS as a treatment option for patients in the NDC will help us improve the treatment when offering it in other clinics, which may help improve smoking quit rates and people's overall health.
CONDITIONS
Official Title
Implementation of Transcranial Magnetic Stimulation for Smoking Cessation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who smoke cigarettes daily
- Health care providers currently working at the CAMH Nicotine Dependence Clinic
- Health care providers involved in the care of at least one patient receiving rTMS for smoking cessation
You will not qualify if you...
- Presence of any intracranial implant or metal object near the head that cannot be safely removed (excluding the mouth)
- Pregnant or intending to become pregnant during the study
- History of primary seizure disorder, seizures associated with brain lesions, recurrent seizures due to substance use or withdrawal, or seizure within the last 6 months
- Taking anticonvulsant medication unless it cannot be safely stopped
- Taking benzodiazepines at or above lorazepam 2mg/day unless it cannot be safely stopped
- Presence of a space-occupying intracranial lesion
- Acutely unstable medical, psychiatric, or substance use disorders posing safety concerns as determined by study physicians
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Center for Addiction and Mental Health (CAMH)
Toronto, Ontario, Canada
Actively Recruiting
Research Team
A
Alexandra S, BScH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here